±èÁÖÇ×
¾ÏÁ¤¹ÐÀÇ·á¼¾ÅÍÀå
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : Æó¾Ï, µÎ°æºÎ¾Ï, ½Äµµ¾Ï
Á÷
ˤ
: ±³¼ö(¾ÏÁ¤¹ÐÀÇ·á¼¾ÅÍÀå)
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
54
ÇØ¿Ü
Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells
53
ÇØ¿Ü
VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth
52
ÇØ¿Ü
Hybrid nanoparticles for magnetic resonance imaging of target-specific viral gene delivery
51
ÇØ¿Ü
Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type
50
ÇØ¿Ü
Treatment outcomes of 70 cases of early esophageal carcinoma: 12 years of experience
49
ÇØ¿Ü
E1A- and E1B-double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects
48
±¹³»
Multi-disciplinary treatment of a rare pelvic cavity ependymoma
47
ÇØ¿Ü
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib
46
ÇØ¿Ü
Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer
45
ÇØ¿Ü
Adenosine Tiphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer
1
2
3
4
5
6
7
8
9
10
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729